Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTA NASDAQ:IMRX NASDAQ:LVTX NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$8.82-2.0%$7.72$4.09▼$13.37$179.57M0.84137,887 shs220,981 shsIMRXImmuneering$5.37-10.4%$4.07$1.10▼$6.35$208.83M0.43859,387 shs850,006 shsLVTXLAVA Therapeutics$1.57+0.6%$1.46$0.85▼$2.09$41.30M0.5153,275 shs69,631 shsSPROSpero Therapeutics$2.08+1.5%$2.34$0.51▼$3.22$116.49M1.46673,687 shs291,283 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals-2.00%+3.40%+24.23%+22.33%-30.11%IMRXImmuneering-10.35%+3.47%+56.56%+161.95%+343.80%LVTXLAVA Therapeutics+0.64%+1.29%+6.80%+20.77%0.00%SPROSpero Therapeutics+1.46%+5.05%-7.96%-18.75%+55.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTAEnanta Pharmaceuticals3.7863 of 5 stars3.50.00.04.72.92.50.0IMRXImmuneering3.126 of 5 stars3.32.00.00.02.05.00.6LVTXLAVA Therapeutics1.2615 of 5 stars3.03.00.00.01.40.00.0SPROSpero Therapeutics4.4646 of 5 stars3.35.00.04.73.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 3.00Buy$22.25152.27% UpsideIMRXImmuneering 2.60Moderate Buy$13.00142.09% UpsideLVTXLAVA Therapeutics 2.00Hold$2.6971.02% UpsideSPROSpero Therapeutics 2.50Moderate Buy$5.00140.38% UpsideCurrent Analyst Ratings BreakdownLatest LVTX, IMRX, ENTA, and SPRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ENTAEnanta PharmaceuticalsWestpark CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$24.008/26/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.008/14/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.008/12/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$24.00 ➝ $25.008/5/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$1.50 ➝ $1.248/5/2025LVTXLAVA TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$3.00 ➝ $1.507/28/2025ENTAEnanta PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.006/18/2025IMRXImmuneeringMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.006/18/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/18/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/5/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$67.64M2.79N/AN/A$3.71 per share2.38IMRXImmuneering$320K609.50N/AN/A$0.80 per share6.71LVTXLAVA Therapeutics$11.98M3.45N/AN/A$0.76 per share2.07SPROSpero Therapeutics$47.98M2.44N/AN/A$0.58 per share3.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$116.04M-$4.32N/AN/AN/A-141.98%-89.02%-27.28%N/AIMRXImmuneering-$61.04M-$1.89N/AN/AN/AN/A-146.28%-117.22%11/12/2025 (Estimated)LVTXLAVA Therapeutics-$25.11M-$1.05N/AN/AN/AN/A-106.29%-38.24%N/ASPROSpero Therapeutics-$68.57M-$0.98N/AN/AN/A-110.35%-120.27%-55.61%11/13/2025 (Estimated)Latest LVTX, IMRX, ENTA, and SPRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025IMRXImmuneering-$0.40-$0.40N/A-$0.40N/AN/A8/13/2025Q2 2025LVTXLAVA Therapeutics-$0.28-$0.32-$0.04-$0.32N/AN/A8/12/2025Q2 2025SPROSpero Therapeutics-$0.38-$0.03+$0.35-$0.03$11.00 million$14.19 million8/11/2025Q3 2025ENTAEnanta Pharmaceuticals-$1.25-$0.85+$0.40-$0.85$16.21 million$18.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A5.005.00IMRXImmuneeringN/A3.703.70LVTXLAVA TherapeuticsN/A10.7810.78SPROSpero TherapeuticsN/A3.973.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%IMRXImmuneering67.65%LVTXLAVA TherapeuticsN/ASPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals13.89%IMRXImmuneering22.90%LVTXLAVA Therapeutics9.50%SPROSpero Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableIMRXImmuneering6036.32 million28.00 millionNot OptionableLVTXLAVA Therapeutics6026.31 million23.81 millionOptionableSPROSpero Therapeutics15056.28 million53.18 millionOptionableLVTX, IMRX, ENTA, and SPRO HeadlinesRecent News About These CompaniesAnson Funds Management LP Has $5.50 Million Position in Spero Therapeutics, Inc. $SPROAugust 26, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Stock Passes Above 200-Day Moving Average - Here's What HappenedAugust 25, 2025 | marketbeat.comDown 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a TurnaroundAugust 19, 2025 | zacks.comSpero Therapeutics (NASDAQ:SPRO) Releases Earnings Results, Beats Expectations By $0.32 EPSAugust 14, 2025 | marketbeat.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | insidermonkey.comSpero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateAugust 13, 2025 | finanznachrichten.deSpero Therapeutics Reports Q2 2025 Results and Trial SuccessAugust 13, 2025 | msn.comSpero Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comSpero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comSpero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business UpdateAugust 12, 2025 | globenewswire.comSpero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025August 5, 2025 | globenewswire.comWhile institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownershipJune 28, 2025 | finance.yahoo.comSpero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo FinanceJune 26, 2025 | finance.yahoo.comSpero Therapeutics -- Additional Upside Potential Following Positive Phase 3 ResultsJune 11, 2025 | seekingalpha.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | msn.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | insidermonkey.comGSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMCMay 30, 2025 | pharmabiz.comPSpero Therapeutics rockets on positive Phase III study for tebipenem HBrMay 29, 2025 | thepharmaletter.comTSpero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 MilestoneMay 29, 2025 | msn.comSPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study GoalMay 29, 2025 | zacks.comGSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soarsMay 28, 2025 | endpts.comENew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAmazon Stock Sets Up for Breakout After Bullish CrossoverBy Sam Quirke | August 21, 2025If Qualcomm Holds $145, Its Next Move Could Be MassiveBy Sam Quirke | August 12, 2025Zillow Group Approaching Key Technical Levels: Is It Time to Buy?By Dan Schmidt | August 23, 2025CrowdStrike Stock Slides—Is Growth Momentum Tapping Out?By Chris Markoch | August 7, 20253 Reasons Salesforce Is a Bargain Right NowBy Sam Quirke | August 22, 2025LVTX, IMRX, ENTA, and SPRO Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$8.82 -0.18 (-2.00%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$8.83 +0.01 (+0.11%) As of 09/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Immuneering NASDAQ:IMRX$5.37 -0.62 (-10.35%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$5.47 +0.10 (+1.86%) As of 09/3/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.LAVA Therapeutics NASDAQ:LVTX$1.57 +0.01 (+0.64%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 09/3/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Spero Therapeutics NASDAQ:SPRO$2.08 +0.03 (+1.46%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$2.05 -0.03 (-1.44%) As of 09/3/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
